CR Boya Bio-pharmaceutical reports profit surge despite revenue drop

CR Boya Bio-pharmaceutical, a subsidiary of China Resources Pharmaceutical Group (HKEX:3320), reported its financial results for the year ended December 31, 2024. While revenue decreased by 34.58% to RMB 1,734.9 million, net profit attributable to shareholders surged by 67.18% to RMB 396.99 million. Excluding extraordinary gains or losses, net profit attributable to shareholders still saw a significant rise of 110.77% to RMB 301.57 million. Basic and diluted earnings per share both increased by 68.09% to RMB 0.79. Net cash flow from operating activities decreased by 53.29% to RMB 299.78 million. Total assets increased by 7.31% to RMB 8,401.14 million, and net assets attributable to shareholders increased by 2.29% to RMB 7,487.15 million. CR Boya Bio-pharmaceutical is proposing a cash dividend of RMB 1.60 per 10 shares, subject to shareholder approval.